Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

ConclusionsThe CDK4/6 pathway is feasible as a potential target for the treatment of bladder cancer, especially in combination with immunotherapy. A CDK4/6 inhibitor should not be combined with gemcitabine.

Source: Cancer Immunology, Immunotherapy - June 5, 2020 Category: Cancer & Oncology Source Type: research